Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 601-601-6 | CAS number: 119345-04-9
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Experimental ADME data are not available for DOWFAX 2A1 surfactant. QSAR programs were used to assess the ADME potential of two major alkylated components of DOWFAX 2A1 in humans.
Based on the systemic bioavailability predictions for DOWFAX 2A1, both oral and dermal bioavailability were conservatively set to 50%, whereas systemic inhalation bioavailability was set to 100%. DOWFAX 2A1 metabolites would be mainly excreted via urine and feces.
On the basis of low volume of distribution, and predicted metabolism and excretion, DOWFAX 2A1 is not expected to bioaccumulate in humans.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
See attached for full discussion of toxicokinetic potential and ADME report of DOWFAX 2A1.
Experimental data on absorption, distribution, metabolism and excretion (ADME) are not available for DOWFAX 2A1 surfactant. To assess the ADME potential of the major monoalky and dialkyl diphenyl ether sulfates components of DOWFAX 2A1 in humans, QSAR programs, ADMET predictor (v7.2, Simulations Plus Inc, Lancaster, CA, USA) and GastroPlus (v9.0, Simulations Plus Inc, Lancaster, CA, USA) were used.
Based on the 90-day repeated exposure scenario at the dose level of 9 mg/kg/day, the predicted oral fractional absorption (Fa%), CYP based metabolism related bioavailability (%), AUC0-2160 (area under curve, µg h/mL) value for the most abundant monoalkyl diphenyl ether sulfate DOWFAX 2A1 component in humans by GastroPlus were 25.7%, 14.9%, and 30800, respectively. In the same exposure scenario, the predicted oral fractional absorption (Fa%), CYP based metabolism related bioavailability (%), AUC0-2160 (area under curve, µg h/mL) value for the dialkyl diphenyl ether sulfate component in humans by GastroPlus were 94.8%, 55.0%, and 11800, respectively.
Based on 90-day repeated exposure scenario at the dose level of 90 mg/kg/day, the predicted dermal fractional absorption (Fa%), CYP based metabolism related bioavailability (%), AUC0-2160 (area under curve, µg h/mL) value for the monoalkyl diphenyl ether sulfate component in humans by GastroPlus were 0.16%, 0.00%, and 0.00%, respectively. In the same exposure scenario, the predicted dermal fractional absorption (Fa%), CYP based metabolism related bioavailability (%), AUC0-2160 (area under curve, µg h/mL) value for the dialkyl diphenyl ether sulfate component in humans by GastroPlus were 0.00277%, 0.00%, and 0.00%, respectively. Thus, DOWFAX 2A1 is not predicted to be systemically bioavailable in humans via dermal exposure route.
Based on the systemic bioavailability predictions for DOWFAX 2A1, both oral and dermal bioavailability were conservatively set to 50%, whereas systemic inhalation bioavailability was adjusted to 100% for DNEL derivation.
The major predicted CYP-dependent DOWFAX 2A1 metabolites were various monohydroxylates on the alkyl side chains and can be further metabolized to water soluble metabolites (such as glucuronides and sulfates). DOWFAX 2A1 metabolites would be mainly excreted via urine and feces.
On the basis of low volume of distribution, and predicted metabolism and excretion, DOWFAX 2A1 is not expected to bioaccumulate in humans.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
